Academic Journal
Balancing efficacy and portability: comparative in vitro/in vivo evaluation of MDI PLUS® versus AeroChamber2go™ spacers for aerosol delivery.
| Τίτλος: | Balancing efficacy and portability: comparative in vitro/in vivo evaluation of MDI PLUS® versus AeroChamber2go™ spacers for aerosol delivery. |
|---|---|
| Συγγραφείς: | Sobh AHM; Clinical Pharmacy Department, Faculty of Pharmacy, University of Mashreq, Baghdad, Iraq., Mohsen M; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-suef University, Beni-suef, Egypt., Abdelfattah AM; Clinical Pharmacy Department, Faculty of Pharmacy, King Salman International University (KSIU), Ras Sudr, Egypt., Abdelrahim MEA; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-suef University, Beni-suef, Egypt., Mohamed BME; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-suef University, Beni-suef, Egypt. |
| Πηγή: | The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2025 Dec; Vol. 62 (12), pp. 2054-2059. Date of Electronic Publication: 2025 Sep 01. |
| Τύπος έκδοσης: | Journal Article; Comparative Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8106454 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-4303 (Electronic) Linking ISSN: 02770903 NLM ISO Abbreviation: J Asthma Subsets: MEDLINE |
| Imprint Name(s): | Publication: London : Informa Healthcare Original Publication: [Ossining, N.Y. : Asthma Publications Society, c1981- |
| Ιατρικοί όροι (MeSH): | Albuterol*/administration & dosage , Albuterol*/urine , Albuterol*/pharmacokinetics , Asthma*/drug therapy , Bronchodilator Agents*/administration & dosage , Bronchodilator Agents*/urine , Bronchodilator Agents*/pharmacokinetics , Metered Dose Inhalers* , Inhalation Spacers*, Humans ; Male ; Adult ; Female ; Administration, Inhalation ; Aerosols ; Middle Aged ; Young Adult ; Drug Delivery Systems |
| Περίληψη: | Background: The Global Initiative for Asthma (GINA) recommended using spacers or valved holding chambers to counter the common problems of poor pressurized metered dose inhaler (pMDI) technique. However, many subjects avoid using conventional spacers because they are bulky and inconvenient to carry around in public. Objective: We aimed to compare the novel, MDI PLUS® spacer, with AeroChamber2go™ on their in vitro and in vivo aerosol performance, as well as their user training requirements. Methods: In vitro, aerosol characteristics were assessed using an Andersen cascade impactor at 28.3 L/min with Ventolin® pMDI (5 puffs, 100 µg/puff); HPLC quantified drug deposition on each stage. In vivo, 20 asthmatic subjects received 500 µg salbutamol via pMDI alone, and pMDI + AeroChamber2go™ or MDI PLUS®. Urine samples were collected at 30 min and cumulatively over 24 h after inhaler use, and salbutamol samples were extracted and assessed using HPLC. Ex vivo delivery and user inhaler mastery were also assessed. Results: The fine-particle dose increased from 94.98 µg (pMDI alone) to 128.45 µg with AeroChamber2go™ and 130.04 µg with MDI PLUS®, while the fine-particle fraction rose from 26.58% to 65.72% and 67.19%, respectively (p < .05). Thirty-minute urinary salbutamol excretion nearly doubled with both the MDI PLUS® and the AeroChamber2go, whereas systemic bioavailability over 24 h was significantly reduced from 143.35 µg with pMDI alone to approximately 60 µg with either device (p < .01). Notably, MDI PLUS required the fewest training sessions to master (1.03, p < .05). Conclusions: Both the MDI PLUS® and the AeroChamber2go™ significantly enhanced pulmonary delivery and reduced systemic exposure compared to pMDI alone, while MDI PLUS® might potentially show a superior ease of use. These findings support the adoption of either device to optimize inhaler therapy. |
| Contributed Indexing: | Keywords: AeroChamber2go; MDI PLUS; fine particle fraction; in vitro; in vivo |
| Substance Nomenclature: | QF8SVZ843E (Albuterol) 0 (Aerosols) 0 (Bronchodilator Agents) |
| Entry Date(s): | Date Created: 20250901 Date Completed: 20251120 Latest Revision: 20260905 |
| Update Code: | 20260905 |
| DOI: | 10.1080/02770903.2025.2552742 |
| PMID: | 40888649 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!